InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
fredman Free
01/03/13 10:14 AM
profile icon
fredman Free
11/28/12 12:05 PM
profile icon
fredman Free
11/27/12 3:16 PM
profile icon
Seshet Free
11/20/12 2:30 AM
profile icon
surf1944 Free
11/19/12 8:36 AM
profile icon
fredman Free
11/19/12 7:00 AM
profile icon
MissionIR Free
11/05/12 10:04 AM
profile icon
surf1944 Free
09/28/12 8:51 AM
profile icon
surf1944 Free
07/03/12 9:12 AM
profile icon
wpa210 Free
06/22/12 10:01 AM
profile icon
Kinny Free
06/21/12 1:04 PM
profile icon
otcbloodhound Free
04/04/12 5:52 PM
profile icon
surf1944 Free
04/03/12 11:08 AM
profile icon
RNsidersbuying Free
03/15/12 11:32 AM
profile icon
RNsidersbuying Free
03/14/12 10:44 AM
profile icon
fredman Free
03/10/12 8:42 AM
profile icon
Penny Roger$ Free
03/09/12 4:23 AM
profile icon
surf1944 Free
02/07/12 1:18 PM
profile icon
mlkrborn Free
01/04/12 8:45 PM
profile icon
manny t Free
10/19/11 10:35 AM
profile icon
mlkrborn Free
10/19/11 10:14 AM
profile icon
read_this_n0w Free
10/06/11 3:52 PM
profile icon
fredman Free
10/05/11 10:04 AM
profile icon
fredman Free
09/22/11 7:21 PM
profile icon
surf1944 Free
07/19/11 11:56 PM
profile icon
surf1944 Free
07/19/11 11:55 PM
profile icon
Frankiy Free
07/12/11 2:16 PM
profile icon
fredman Free
06/28/11 8:41 AM
profile icon
sterlingkuning Free
06/13/11 10:26 AM
profile icon
arigold0702 PremiumMember
06/09/11 11:13 AM
profile icon
sterlingkuning Free
06/08/11 7:49 AM
profile icon
sterlingkuning Free
06/07/11 1:46 PM
profile icon
fredman Free
06/07/11 9:21 AM
profile icon
sterlingkuning Free
06/06/11 10:20 AM
profile icon
sterlingkuning Free
06/06/11 10:15 AM
profile icon
sterlingkuning Free
06/06/11 10:00 AM
profile icon
sterlingkuning Free
06/06/11 9:56 AM
profile icon
sterlingkuning Free
06/06/11 9:48 AM
profile icon
fredman Free
06/02/11 3:42 PM
profile icon
arigold0702 PremiumMember
06/02/11 3:29 PM
profile icon
fredman Free
05/31/11 5:25 PM
profile icon
manny t Free
05/31/11 4:49 PM
profile icon
sterlingkuning Free
05/31/11 4:35 PM
profile icon
fredman Free
05/31/11 4:24 PM
profile icon
fredman Free
05/31/11 9:51 AM
profile icon
arigold0702 PremiumMember
05/31/11 9:35 AM
profile icon
arigold0702 PremiumMember
05/27/11 9:32 AM

BioMimetic Therapeutics, Inc. (BMTI) RSS Feed

Followers
5
Posters
25
Posts (Today)
0
Posts (Total)
164
Created
04/03/08
Type
Free
Moderators

BioMimetic Therapeutics, Inc.
389 Nichol Mill Lane
Franklin, TN 37067   USA
615-844-1280

http://www.biomimetics.com/

BMTI SEC Filings


BMTI Annual Report
 

BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of innovative drug-device combination products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, spine and sports injury applications. All products developed by BioMimetic are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology, which is a synthetic form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments, thus helping patients recover faster from their orthopedic injuries.
In 2005, BioMimetic received marketing approval from the FDA for its first product, GEM 21S, as a grafting material for bone and periodontal regeneration.  Additionally, BioMimetic Therapeutics has completed and continues to sponsor clinical trials with its three lead product candidates Augment Bone Graft, Augment Injectable Bone Graft, and Augment  Rotator Cuff Graft  in multiple orthopedic and sports medicine indications including the treatment of foot and ankle fusions, the stimulation of healing of fractures of the wrist and the surgical treatment of rotator cuff tears.

In November 2009, BioMimetic received approval from Health Canada to begin marketing Augment as an alternative to the use of autograft in foot and ankle fusion indications in Canada.

In May 2010, the Company's Pre-Marketing Approval (PMA) application for the approval of Augment Bone Graft was filed with the FDA.

On May 12, 2011, the U.S. Food and Drug Administration's Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee voted favorably on Augment Bone Graft's safety, efficacy and benefit to risk profile for its use as an alternative to autograft in hindfoot and ankle fusions.

On May 17, 2011, BioMimetic was awarded US Patent # (7,943,573)  "Methods for treatment of Distraction Osteogenesis using PDGF." 

Institutional Investors of BioMimetic Therapeutics

Novo A/S     4,720,065 Shares
TCW Group, INC.     2,526,512 Shares
Clearbridge Advisors, LLC     1,897,137 Shares
Legg Mason Clearbridge Aggressive Growth Fund     1,452,600 Shares
GLG Partners LP     1,404,229 Shares
TCW Small Cap Growth Fund     1,273,000 Shares
Visium Asset Management     907,939 Shares
Vanguard Group, INC.     749,701 Shares
Sectoral Asset Management, INC.     687,735 Shares
BlackRock Fund Advisors     623,054 Shares
Barclays Global Investors     607,809 Shares     
Interfund Equity USA     556,700 Shares
BlackRock Institutional Trust Company, N.A.     540,085 Shares
Emerald Advisors     509,674 Shares
Perceptive Advisors LLC     500,800 Shares
Wall Street Associates     487,800 Shares
UBS Global Asset Management     391,929 Shares
Vanguard Small-Cap Growth Index Fund     318,288 Shares
State Street Corporation     312,325 Shares
SEI Trust Company     279,895 Shares
AB International Fund     269,100 Shares
IShares Russell 2000 Index Fund     247,286 Shares
ING Patrners Inc. / Legg Mason Partners Aggressive Growth     212,520 Shares
Legg Mason Part Var Eq TR -LM Clearbridge Var Aggressive Growth     208,410 Shares
Ameriprise Financial, INC.     207,160 Shares
Riversource VP Partners Small Cap Growth Fund     205,750 Shares
IShares NASDAQ Biotchnology Index Fund     185,408 Shares
J.P. Morgan Chase & Company     178,500 Shares
Fidelity Select Portfolios - Pharmaceuticals     160,000 Shares

Recent Insider Transactions

Gary E Friedlaender, Director of BioMimetic Therapeutics PURCHASED 7,500 Shares @ $7.96 on 4/25/11 
Samuel E. Lynch, President and CEO of BioMimetic Therapeutics PURCHASED 10,000 Shares @ $7.90 and 3,000 shares @ $7.75 on 5/18/11
Russell Pagano, VP / Regulatory & Clinical Affairs of BioMimetic Therapeutics PURCHASED 1,900 Shares @ $7.9493 on 5/19/11 

 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
BMTI Latest News
  • No Recent News Available for this company!
New Post